Prot #BAY 59-7939/17454: An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients with Symptomatic Pe

Project: Research project

Project Details

Effective start/end date1/28/161/28/19


  • Covance Inc. (BAY 59-7939/17454)
  • Bayer HealthCare Pharmaceuticals, Inc. (BAY 59-7939/17454)